B-RAF with PLX4032
From Proteopedia
(Difference between revisions)
| Line 10: | Line 10: | ||
<scene name='B-RAF_with_PLX4032/Mutated_v600e/1'>V600E Mutation</scene> <br> | <scene name='B-RAF_with_PLX4032/Mutated_v600e/1'>V600E Mutation</scene> <br> | ||
<scene name='B-RAF_with_PLX4032/Plx4032_n/1'>PLX4032 Sulfonamide N</scene> <br> | <scene name='B-RAF_with_PLX4032/Plx4032_n/1'>PLX4032 Sulfonamide N</scene> <br> | ||
| - | <scene name='B-RAF_with_PLX4032/H-bond/ | + | <scene name='B-RAF_with_PLX4032/H-bond/4'>H-Bond Interaction Asp594 and PLX4032</scene><br> |
<scene name='B-RAF_with_PLX4032/Dfg_in_conformation/1'>DFG in</scene><br> | <scene name='B-RAF_with_PLX4032/Dfg_in_conformation/1'>DFG in</scene><br> | ||
<scene name='B-RAF_with_PLX4032/Phe_595_dfg_out/1'>DFG out</scene><br> | <scene name='B-RAF_with_PLX4032/Phe_595_dfg_out/1'>DFG out</scene><br> | ||
Revision as of 18:16, 7 October 2010
B-RAF with PLX4032
PLX4032 is a newly synthesized drug that is being used to treat malignant melanoma with a specific mutation. The mutation is B-RAF^(V600E). This drug is highly selective for this mutation and will not bind to wild type B-RAF.
|
